Catalent has formed a collaboration with a privately held Australian biomarker research company, Minomic International Limited, to develop MIL-38, an antibody drug conjugate (ADC) for prostate cancer therapy. Under the agreement, Catalent will initially produce the antibody for a clinical study with a view to larger scale production subject to a successful outcome.

The antibody production project incorporates Catalent’s proprietary GPEx technology, which creates mammalian cell lines. Should the initial clinical study prove successful, the antibody will be produced at Catalent’s biomanufacturing facility in Madison, Wisconsin.

Catalent’s Madison biomanufacturing facility was constructed through an investment of approximately $20 million and completed in June 2013, quadrupled the company’s biologics manufacturing capacity. The facility offers cGMP production from 10 liters up to 1000 liters and non-GMP production up to 250 liters.

Source: Catalent